Last updated: July 31, 2026
Diatrizoate meglumine and diatrizoate sodium are mature, low-growth iodinated contrast media used mainly for gastrointestinal radiography and CT imaging. The principal commercial product is Gastrografin, an oral and rectal solution combining both salts. The products have no meaningful composition-of-matter exclusivity remaining, face generic and multisource competition, and generate limited standalone revenue disclosure because manufacturers report them within broader contrast-media portfolios. Commercial value depends on hospital formulary retention, manufacturing reliability, radiology procedure volumes, and supply availability rather than patent protection.
What are diatrizoate meglumine and diatrizoate sodium used for?
Diatrizoate is a water-soluble, high-osmolality, ionic iodinated contrast agent. The meglumine and sodium salts provide the active iodine-containing contrast component.
Gastrografin is labeled for oral or rectal administration in radiographic examination of the gastrointestinal tract. It is also used in selected CT examinations when gastrointestinal opacification is required. The product contains approximately 660 mg iodine/mL and is hyperosmolar relative to plasma. Its labeled uses include examination of suspected gastrointestinal obstruction and other diagnostic studies of the esophagus, stomach, small bowel, and colon (Bracco Diagnostics Inc., 2023).
Product and formulation profile
| Attribute |
Diatrizoate meglumine |
Diatrizoate sodium |
Gastrografin combination |
| Primary role |
Ionic iodinated contrast salt |
Ionic iodinated contrast salt |
Oral/rectal GI contrast solution |
| Main route |
Oral or rectal in combination products; injectable presentations historically marketed |
Oral, rectal, and injectable presentations historically marketed |
Oral or rectal |
| Typical clinical use |
GI tract imaging |
GI tract and radiographic contrast applications |
GI imaging and selected CT procedures |
| Osmolality |
High |
High |
Very high |
| Patent status |
Mature compound |
Mature compound |
Mature formulation and brand |
| Current competitive basis |
Availability, price, labeling, supply |
Availability, price, labeling, supply |
Formulary position and manufacturing continuity |
The products are pharmacologically distinct from newer nonionic agents such as iohexol, iopamidol, ioversol, and iodixanol. Newer agents are used predominantly for intravascular CT and angiography, while diatrizoate remains concentrated in gastrointestinal applications.
What is the FDA regulatory status of diatrizoate meglumine and diatrizoate sodium?
The products are FDA-approved prescription contrast agents. Gastrografin is an approved drug product with labeling covering oral and rectal administration. Diatrizoate sodium and diatrizoate meglumine have also been marketed in injectable and gastrointestinal dosage forms, although the commercial availability of specific presentations has changed over time.
The product category is regulated as a drug rather than as a medical device. Manufacturers must comply with FDA drug manufacturing, labeling, adverse-event reporting, and application requirements. Because the active ingredients are old and widely established, regulatory differentiation generally depends on dosage form, route, concentration, manufacturing controls, and labeling rather than novel clinical pharmacology.
FDA regulatory characteristics
| Regulatory factor |
Market implication |
| Approved drug status |
Supports hospital and radiology use without a new-drug clinical development program for each generic equivalent |
| Established active ingredients |
Low barriers to basic product development |
| High-concentration aqueous solution |
Manufacturing and stability controls remain important |
| Oral and rectal routes |
Limits competition to products with equivalent labeling and usable administration formats |
| High osmolality |
Requires prominent safety labeling and restricts use in certain patients |
| Drug shortage exposure |
Increases the commercial value of reliable supply even without patent protection |
The labeling identifies risks associated with aspiration, dehydration, fluid shifts, and use in patients with suspected perforation or compromised gastrointestinal integrity. These safety considerations affect hospital protocols and can favor products with established institutional experience (Bracco Diagnostics Inc., 2023).
What patents protect diatrizoate meglumine and diatrizoate sodium?
No commercially meaningful patent estate protects the underlying diatrizoate molecules. Diatrizoic acid and its salts were introduced decades ago, placing composition-of-matter patents far outside their enforceable terms.
The modern patent position is therefore different from that of recently approved contrast agents. Market access is not controlled by an active compound patent, a platform patent, or a biologic exclusivity period. Any remaining intellectual-property rights would more likely concern a particular container, administration system, manufacturing process, or ancillary formulation rather than the active ingredient itself.
Patent and exclusivity assessment
| Protection category |
Current commercial relevance |
| Composition-of-matter patent |
Expired |
| Salt-form patent |
Expired or commercially immaterial |
| Basic formulation patent |
Expired or immaterial for standard products |
| Method-of-use patent |
No material barrier identified for established GI indications |
| Orange Book patent listing |
No active patent barrier of practical significance for standard diatrizoate products |
| Regulatory exclusivity |
Expired for legacy products |
| Trade secret protection |
Potentially relevant to manufacturing efficiency and quality control |
| Trademark protection |
Relevant to Gastrografin branding, not generic market access |
The FDA Orange Book remains the primary source for checking active listed patents and regulatory exclusivity associated with approved drug applications. For legacy diatrizoate products, the commercial position is consistent with a patent-expired multisource market rather than an exclusivity-protected franchise (U.S. Food and Drug Administration, 2024a).
When does diatrizoate lose exclusivity?
Diatrizoate meglumine and diatrizoate sodium lost meaningful regulatory and patent exclusivity decades ago. There is no current exclusivity cliff comparable to the loss of protection for a recent branded drug.
The relevant commercial event is not patent expiry. It is the continuing erosion of demand and margin as hospitals substitute alternative contrast products, consolidate purchasing, and use imaging protocols that reduce the need for oral or rectal high-osmolality agents.
Exclusivity timeline
| Period |
Market status |
| Original commercialization |
Branded, innovator-controlled contrast products |
| Patent-expiry period |
Entry by generic and multisource manufacturers |
| Mature market period |
Price competition and hospital purchasing pressure |
| Current market |
Brand recognition remains, but supply and procurement determine access |
A Paragraph IV challenge is unlikely to be a central market event because standard diatrizoate products do not depend on an active patent barrier. Generic applicants can pursue abbreviated pathways or other FDA routes applicable to the specific product and dosage form. The principal risks are product discontinuation, manufacturing constraints, and formulation differences rather than patent litigation.
What is the Orange Book status of Gastrografin and generic diatrizoate?
The Orange Book is relevant for identifying approved applications, therapeutic-equivalence information, and any listed patents or exclusivity. Gastrografin’s current commercial value does not appear to derive from active Orange Book patent protection. Generic and alternative diatrizoate products compete primarily through approval status, labeling, price, and supply.
Therapeutic equivalence can be complicated by differences in concentration, route, dosage form, packaging, and labeled use. A hospital may treat two products as operational substitutes without treating them as identical products for every regulatory purpose.
Generic substitution considerations
Hospitals and distributors evaluate:
- iodine concentration;
- diatrizoate meglumine-to-sodium ratio;
- oral versus rectal labeling;
- bottle size and unit-dose configuration;
- compatibility with feeding tubes and radiology workflows;
- package labeling and administration instructions;
- supply continuity;
- wholesaler availability;
- contract pricing.
The brand may retain a price premium where clinicians associate it with established performance or where a hospital has standardized its protocols around the product. That premium is a commercial effect, not patent protection.
What formulations are protected by diatrizoate patents?
The main formulation of commercial interest is the Gastrografin oral and rectal solution containing diatrizoate meglumine and diatrizoate sodium. The formulation is differentiated by its salt combination, iodine concentration, excipients, packaging, and labeling.
There is no indication that the standard Gastrografin formulation is protected by a current formulation patent that prevents generic competition. Formulation-related know-how can still affect product quality. High-osmolality solutions require control of concentration, pH, impurities, container interaction, microbial quality, and long-term stability.
Manufacturing and IP barriers
Manufacturing barriers are operational rather than exclusionary. They include:
- sourcing pharmaceutical-grade diatrizoic acid and salt intermediates;
- maintaining validated blending and filling processes;
- controlling iodine concentration and solution uniformity;
- qualifying containers and closures;
- meeting sterile or nonsterile requirements for the relevant dosage form;
- maintaining FDA-compliant quality systems;
- securing reliable distribution to hospitals and radiology centers.
These requirements can reduce the number of active suppliers even when the product has no enforceable patent. A concentrated, low-volume product can become vulnerable to shortages if only a small number of manufacturers maintain commercial-scale production.
How strong is the patent estate for diatrizoate versus newer contrast agents?
Diatrizoate has a weak patent estate but a long commercial history. Newer contrast agents have stronger historical patent positions and broader use in intravascular imaging.
| Product class |
Patent position |
Main commercial use |
Pricing power |
| Diatrizoate meglumine/sodium |
Mature and effectively off-patent |
Oral and rectal GI imaging |
Low |
| Iohexol |
Mature; generic competition in many markets |
CT, angiography, intravascular imaging |
Moderate |
| Iopamidol |
Mature; generic competition |
CT and angiography |
Moderate |
| Ioversol |
Mature; generic competition |
CT and angiography |
Moderate |
| Iodixanol |
Higher-value nonionic, iso-osmolar segment |
Selected intravascular procedures |
Higher than diatrizoate |
| New contrast platforms |
Potential active patents or exclusivity |
Specialized imaging applications |
Variable to high |
The comparison is not purely patent-based. Diatrizoate occupies a narrower therapeutic niche and is often purchased as a low-cost adjunct to imaging procedures. Newer agents benefit from larger procedure volumes and broader use in CT and vascular imaging.
Which companies compete in the diatrizoate market?
Bracco Diagnostics is the most visible branded supplier through Gastrografin. Generic and hospital-distribution competition has varied by country and dosage form. Companies that have marketed diatrizoate products historically include major generic and radiopharmaceutical suppliers, but active participation depends on current FDA approval, manufacturing status, and commercial availability.
The market structure is best described as a branded legacy product surrounded by generic or alternative suppliers rather than a concentrated innovative-drug market. The relevant competitive set includes:
- branded Gastrografin;
- generic diatrizoate meglumine and sodium solutions;
- other oral contrast agents;
- dilute barium preparations;
- water-soluble nonionic contrast products in selected applications;
- imaging protocols that do not require oral contrast.
Barium remains a major alternative for many gastrointestinal studies. Water-soluble iodinated contrast is preferred in situations where leakage, obstruction, postoperative anatomy, or aspiration risk makes barium less suitable.
What is the financial trajectory for diatrizoate products?
Standalone revenue for diatrizoate meglumine and diatrizoate sodium is generally not disclosed by public manufacturers. Gastrografin revenue is typically embedded in broader diagnostic-imaging or contrast-media reporting. The product should therefore be modeled as a mature niche asset rather than as a separately reported growth franchise.
Financial trajectory
| Driver |
Historical effect |
Current effect |
| Patent expiry |
Reduced pricing and increased supplier access |
No remaining exclusivity benefit |
| GI imaging demand |
Supported baseline volume |
Stable to low growth |
| Shift toward newer contrast agents |
Reduced use in some settings |
Continued substitution pressure |
| Hospital procurement |
Increased generic pressure |
Strong effect on net price |
| Supply interruptions |
Created temporary pricing and share shifts |
Can materially affect short-term revenue |
| Brand familiarity |
Supported Gastrografin retention |
Helps preserve a premium in some accounts |
| Manufacturing scale |
Improved unit economics for established suppliers |
Determines long-term margin |
Revenue is likely to be stable to declining in mature markets, with occasional increases caused by price adjustments, supply shortages, or temporary competitor exits. Volume growth is constrained because the product is tied to a specific set of gastrointestinal imaging protocols.
A practical commercial model should separate four variables:
- treated imaging volume;
- share of procedures using water-soluble iodinated contrast;
- supplier share;
- net realized price after hospital contracts and distributor discounts.
The product can remain profitable despite low unit pricing if manufacturing is efficient and distribution is established. Conversely, low annual sales can become unattractive if regulatory maintenance, quality oversight, and supply-chain costs are high relative to volume.
What generic entry risks exist for Gastrografin?
Generic entry risk is already realized rather than prospective. The principal risk to the branded product is continued substitution by lower-priced suppliers and hospital purchasing policies.
Generic launch scenarios
| Scenario |
Likely effect |
| New approved generic supplier enters |
Lower prices and distributor switching |
| Existing supplier exits |
Temporary share gains for remaining manufacturers |
| Gastrografin maintains reliable supply |
Brand retains institutional accounts |
| Hospital converts to a lower-cost product |
Permanent volume loss |
| Alternative oral contrast protocol expands |
Structural demand reduction |
| Manufacturing disruption occurs |
Short-term price and share volatility |
A new generic entrant would not need to overcome a meaningful patent barrier. Its principal challenges would be FDA approval, product-specific bioequivalence or pharmaceutical equivalence requirements where applicable, manufacturing validation, commercial scale, and distributor access.
What patent litigation and settlement agreements affect diatrizoate?
There is no prominent current patent-litigation narrative comparable to disputes involving recently approved medicines. Because the active ingredients and standard use cases are legacy technologies, Paragraph IV litigation and patent settlements are not major drivers of the market.
Commercial disputes are more likely to involve:
- supply contracts;
- quality deviations;
- product recalls;
- distributor agreements;
- manufacturing transfers;
- shortages;
- hospital conversion decisions.
The absence of a major litigation pipeline reduces legal uncertainty but also removes the possibility of patent-based market protection.
What is the geographic coverage of the diatrizoate market?
Diatrizoate products are used internationally, but regulatory status and supplier availability differ by jurisdiction. Gastrografin has broad recognition in hospital markets, while generic availability varies according to national approval systems and reimbursement policies.
North America and Europe have mature demand, established radiology protocols, and strong procurement pressure. Emerging markets may retain demand where water-soluble GI contrast is available at lower cost than newer agents or where imaging infrastructure is expanding. Geographic revenue growth is more likely to come from procedure-volume increases and distribution expansion than from premium pricing.
Is there biosimilar risk for diatrizoate?
Biosimilar risk does not apply. Diatrizoate meglumine and diatrizoate sodium are small-molecule chemical drugs, not biologics. Competition arises from generic drug products, multisource suppliers, alternative contrast media, and different imaging protocols.
How does diatrizoate compare with barium and newer iodinated contrast agents?
Diatrizoate’s main advantage is water solubility and utility when gastrointestinal leakage or obstruction is a concern. Its disadvantages include very high osmolality, aspiration-related safety concerns, and limited use outside GI imaging.
| Attribute |
Diatrizoate |
Barium |
Newer nonionic iodinated agents |
| Water soluble |
Yes |
No |
Yes |
| Typical GI use |
Obstruction, leak evaluation, selected CT |
Routine GI mucosal imaging |
Selected CT and specialized uses |
| Osmolality |
Very high |
Not applicable in the same way |
Generally lower than diatrizoate |
| Cost position |
Low |
Low |
Moderate to high |
| Patent strength |
None of practical significance |
Mature |
Varies by agent |
| Main limitation |
Hyperosmolality and aspiration risk |
Contraindicated or undesirable when leakage is suspected |
Higher cost and intravascular-use considerations |
Key Takeaways
- Diatrizoate meglumine and diatrizoate sodium are mature, off-patent iodinated contrast agents.
- Gastrografin is the principal branded product and combines both salts in an oral and rectal solution.
- No active composition-of-matter or formulation exclusivity is a meaningful barrier to generic competition.
- Paragraph IV litigation, biosimilar competition, and patent settlements are not central market risks.
- Revenue is generally embedded in broader diagnostic-imaging portfolios rather than disclosed as a standalone product line.
- The market is stable to declining in volume, with pricing shaped by hospital procurement and generic substitution.
- Supply reliability, manufacturing quality, and distributor access are more important than intellectual property.
- Competitive pressure comes from generic diatrizoate, barium, newer nonionic agents, and imaging protocols that reduce the need for oral contrast.
- The strongest commercial asset is established clinical familiarity and dependable supply, not patent protection.
FAQs
Does Gastrografin still have patent protection?
Gastrografin does not depend on a commercially meaningful active patent protecting the diatrizoate salts or their standard GI formulation. Its remaining differentiation is primarily brand recognition, labeling, manufacturing quality, and supply reliability.
Is diatrizoate meglumine the same as Gastrografin?
No. Diatrizoate meglumine is one active salt used in Gastrografin. Gastrografin is a finished combination solution containing diatrizoate meglumine and diatrizoate sodium.
Can diatrizoate be replaced by barium?
In some gastrointestinal imaging procedures, yes. Barium is often used for routine mucosal studies, while diatrizoate is favored when a water-soluble agent is clinically preferred, including selected obstruction or leak evaluations.
Why can an off-patent contrast agent remain commercially relevant?
Hospitals continue to need established products for recurring imaging protocols. A supplier can sustain a niche business through manufacturing efficiency, institutional familiarity, distributor relationships, and reliable availability even without patent protection.
What would most improve the financial outlook for diatrizoate products?
The strongest short-term factors would be supplier exits, product shortages affecting competitors, expanded imaging volumes, and successful retention of hospital contracts. Long-term growth is constrained by substitution and the product’s narrow GI-focused use profile.
References
-
Bracco Diagnostics Inc. (2023). Gastrografin (diatrizoate meglumine and diatrizoate sodium) oral or rectal solution: Prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
-
American College of Radiology. (2024). ACR manual on contrast media. American College of Radiology.
-
U.S. Food and Drug Administration. (2024c). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/inspections.cfm
